Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis

1. Rodriguez-­Galindo C. Clinical features and treatment of Langerhans

cell histiocytosis. Acta Paediatr. 2021;110(11):2892-­2902.

2. McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders. Nat

Rev Dis Primers. 2021;7(1):73.

3. Allen CE, Li L, Peters TL, et al. Cell-­specific gene expression in

Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010;184(8):​

4557-­4567.

4. Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath

F. Langerhans'-­cell histiocytosis in adults. Med Pediatr Oncol.

1997;28(1):9-­14.

5. Goyal G, Shah MV, Hook CC, et al. Adult disseminated Langerhans

cell histiocytosis: incidence, racial disparities and long-­term outcomes. Br J Haematol. 2018;182(4):579-­581.

6. Badalian-­Very G, Vergilio JA, Degar BA, et al. Recurrent

BRAF mutations in Langerhans cell histiocytosis. Blood.

2010;116(11):1919-­1923.

7. Berres ML, Lim KP, Peters T, et al. BRAF-­V600E expression in precursor versus differentiated dendritic cells defines clinically distinct

LCH risk groups. J Exp Med. 2014;211(4):669-­683.

8. Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-­year nationwide

20. 21. 22. 23. 24. 25. 26. 27. cohort of 1478 patients under 18 years of age. Br J Haematol.

2016;174(6):887-­898.

Heritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates

with high-­risk Langerhans cell histiocytosis and increased resistance to first-­line therapy. J Clin Oncol. 2016;34(25):3023-­3 030.

Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E

mutation: a significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis. Pediatr Dev Pathol.

2019;22(5):449-­455.

Veillette A, Thibaudeau E, Latour S. High expression of inhibitory receptor SHPS-­1 and its association with protein-­

tyrosine phosphatase SHP-­1 in macrophages. J Biol Chem.

1998;273(35):22719-­2 2728.

Adams S, van der Laan LJ, Vernon-­Wilson E, et al. Signal-­regulatory

protein is selectively expressed by myeloid and neuronal cells. J

Immunol. 1998;161(4):1853-­1859.

Seiffert M, Cant C, Chen Z, et al. Human signal-­regulatory protein is

expressed on normal, but not on subsets of leukemic myeloid cells

and mediates cellular adhesion involving its counterreceptor CD47.

Blood. 1999;94(11):3633-­3643.

Jiang P, Lagenaur CF, Narayanan V. Integrin-­associated protein

is a ligand for the P84 neural adhesion molecule. J Biol Chem.

1999;274(2):559-­562.

Han X, Sterling H, Chen Y, et al. CD47, a ligand for the macrophage

fusion receptor, participates in macrophage multinucleation. J Biol

Chem. 2000;275(48):37984-­37992.

Vernon-­Wilson EF, Kee WJ, Willis AC, Barclay AN, Simmons DL,

Brown MH. CD47 is a ligand for rat macrophage membrane signal

regulatory protein SIRP (OX41) and human SIRPα 1. Eur J Immunol.

2000;30(8):2130-­2137.

Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular mechanisms of the CD47-­SIRPα signalling pathway. Trends Cell

Biol. 2009;19(2):72-­8 0.

Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and

therapeutic target. Annu Rev Immunol. 2014;32:25-­50.

Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown

EJ. In vivo expression of alternatively spliced forms of integrin-­

associated protein (CD47). J Cell Sci. 1995;108(Pt11):3419-­3 425.

Brown EJ, Frazier WA. Integrin-­associated protein (CD47) and its

ligands. Trends Cell Biol. 2001;11(3):130-­135.

Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on

circulating hematopoietic stem cells and leukemia cells to avoid

phagocytosis. Cell. 2009;138(2):271-­285.

Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid

leukemia stem cells. Cell. 2009;138(2):286-­299.

Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-­

signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA.

2012;109(17):6662-­6667.

Zhao XW, van Beek EM, Schornagel K, et al. CD47-­signal regulatory protein-­α (SIRPα) interactions form a barrier for antibody-­

mediated tumor cell destruction. Proc Natl Acad Sci U S A.

2011;108(45):18342-­18347.

Murata Y, Saito Y, Kotani T, Matozaki T. CD47-­signal regulatory protein α signaling system and its application to cancer immunotherapy. Cancer Sci. 2018;109(8):2349-­2357.

Chao MP, Alizadeh AA, Tang C, et al. Anti-­CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-­

Hodgkin lymphoma. Cell. 2010;142(5):699-­713.

Yanagita T, Murata Y, Tanaka D, et al. Anti-­SIRPα antibodies

as a potential new tool for cancer immunotherapy. JCI Insight.

2017;2(1):e89140.

13497006, 2023, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cas.15758 by Kobe University, Wiley Online Library on [08/05/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

1880 28. Ring NG, Herndler-­Brandstetter D, Weiskopf K, et al. Anti-­SIRPα

antibody immunotherapy enhances neutrophil and macrophage

antitumor activity. Proc Natl Acad Sci USA. 2017;114(49):E10578

-­E10585.

29. Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-­

SIRPα signaling axis as an innate immune checkpoint in cancer.

Immunol Rev. 2017;276(1):145-­164.

3 0. Fukunaga A, Nagai H, Noguchi T, et al. Src homology 2 domain-­

containing protein tyrosine phosphatase substrate 1 regulates the

migration of Langerhans cells from the epidermis to draining lymph

nodes. J Immunol. 2004;172(7):4091-­4 099.

31. Okajo J, Kaneko Y, Murata Y, et al. Regulation by Src homology 2

domain-­containing protein tyrosine phosphatase substrate-­1 of α-­

galactosylceramide-­induced antimetastatic activity and Th1 and

Th2 responses of NKT cells. J Immunol. 2007;178(10):6164-­6172.

32. Gruijs M, Sewnath CAN, van Egmond M. Therapeutic exploitation

of neutrophils to fight cancer. Semin Immunol. 2021;57:101581.

33. Hogstad B, Berres ML, Chakraborty R, et al. RAF/MEK/extracellular signal-­related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis

lesions. J Exp Med. 2018;215(1):319-­336.

34. Saito Y, Respatika D, Komori S, et al. SIRPα+ dendritic cells regulate homeostasis of fibroblastic reticular cells via TNF receptor ligands in the

adult spleen. Proc Natl Acad Sci USA. 2017;114(47):E10151-­E10160.

35. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM.

Langerhans-­cell histiocytosis ‘insight into DC biology’. Trends

Immunol. 2003;24(4):190-­196.

36. Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T. Recent advances

in Langerhans cell histiocytosis. Pediatr Int. 2014;56(4):451-­461.

37. Allen CE, Beverley PCL, Collin M, et al. The coming of age of

Langerhans cell histiocytosis. Nat Immunol. 2020;21(1):1-­7.

38. Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC,

Egeler RM. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of

Langerhans cell histiocytosis. J Exp Med. 2003;197(10):1385-­1390.

39. Quispel WT, Stegehuis-­Kamp JA, Blijleven L, et al. The presence

of CXCR4 + CD1a+ cells at onset of Langerhans cell histiocytosis

is associated with a less favorable outcome. Onco Targets Ther.

2016;5(3):e1084463.

4 0. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev

Immunol. 2014;32:659-­702.

41. Eckstein OS, Visser J, Rodriguez-­Galindo C, Allen CE, Group N-­

LS. Clinical responses and persistent BRAF V600E+ blood cells in

children with LCH treated with MAPK pathway inhibition. Blood.

2019;133(15):1691-­1694.

42. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory

multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37(31):2857-­2865.

43. Xu MM, Pu Y, Han D, et al. Dendritic cells but not macrophages

sense tumor mtochondrial DNA for cross-­priming through signal

regulatory protein α signaling. Immunity. 2017;47(2):363-­373 e365.

4 4. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of

monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347(6294):669-­671.

45. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA.

A highly efficacious lymphocyte chemoattractant, stromal cell-­

derived factor 1 (SDF-­1). J Exp Med. 1996;184(3):1101-­1109.

46. Cole KE, Strick CA, Paradis TJ, et al. Interferon-­inducible T cell

alpha chemoattractant (I-­TAC): a novel non-­ELR CXC chemokine

with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998;187(12):2009-­2021.

47. Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM. CC-­

chemokine receptor 6 is expressed on diverse memory subsets of T

cells and determines responsiveness to macrophage inflammatory

protein 3α. J Immunol. 1999;162(1):186-­194.

4 8. van Rees DJ, Brinkhaus M, Klein B, et al. Sodium stibogluconate

and CD47-­SIRPα blockade overcome resistance of anti-­CD20-­

opsonized B cells to neutrophil killing. Blood Adv. 2022;6(7):​

2156-­2166.

49. Gauttier V, Pengam S, Durand J, et al. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest. 2020;130(11):6109-­6123.

50. Sakamoto M, Murata Y, Tanaka D, et al. Anticancer efficacy of

monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages. Proc Natl Acad Sci USA.

2022;119(1):e2109923118.

51. Hayashi A, Ohnishi H, Okazawa H, et al. Positive regulation of

phagocytosis by SIRPβ and its signaling mechanism in macrophages.

J Biol Chem. 2004;279(28):29450-­29460.

S U P P O R T I N G I N FO R M AT I O N

Additional supporting information can be found online in the

Supporting Information section at the end of this article.

How to cite this article: Okamoto T, Murata Y, Hasegawa D,

et al. Targeting of SIRPα as a potential therapy for

Langerhans cell histiocytosis. Cancer Sci. 2023;114:18711881. doi:10.1111/cas.15758

13497006, 2023, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cas.15758 by Kobe University, Wiley Online Library on [08/05/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

1881

OKAMOTO et al.

...